At present, SII sells its vaccine Covishield to the Centre for Rs 150 per dose, to state governments for Rs 300 and to private hospitals for Rs 600.
Mumbai estimates to spend 7 billion rupees to buy shots informed municipal commissioner Iqbal Singh Chahal.
BMC was the first civic body in the country to float a global tender for purchasing vaccines
"Once the devastating outbreak in India recedes, we also need the Serum Institute of India to get back on track and catch up on its delivery commitments to Covax," WHO chief said
Serum Institute of India CEO Adar Poonawalla offloaded his entire stake in Panacea Biotec amounting to 5.15 per cent shareholding of the firm for Rs 118 crore, through an open market transaction
Indian firms need to prepare for export boom by vaccinating employees, their family members; and prioritise export market
Timelines suggest govt must focus on health infra too
SII aims to make 50 million doses of Covovax (the Novavax vaccine) per month at its Pune plant
India has vaccinated 37.2 million people with both doses of a vaccine, and about 135.5 million have received at least the first jab
States told to ensure adherence to revised schedule
To this, the SII said they are doing their best to meet countrywide vaccine requirements.
Serum Institute of India CEO Adar Poonawalla has promised Chief Minister Uddhav Thackeray to deliver 15 million doses of Covishield to Maharashtra after May 20, said the state health minister
The health minister was holding a meeting with eight states that have been showing a higher number of daily cases, positivity rate and mortality
Delhi's Deputy Chief Minister Manish Sisodia accused the Centre of blocking supplies to the state.
Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September. The Hyderabad-based Bharat Biotech's indigenously developed Covaxin and Oxford-AstraZeneca's Covishield, being manufactured by the Pune-based Serum Institute of India, are currently being used in India's inoculation drive against coronavirus. Dr V Krishna Mohan, the Whole-time Director of Bharat Biotech, is learnt to have conveyed to the government that the production of Covaxin would be raised to 3.32 crore in July, and to 7.82 crore in August which will be maintained in September too. Similarly, Prakash Kum
For both companies, the pandemic presents a once-in-a-lifetime opportunity to earn hundreds of crores of rupees that could be ploughed back to fund further research and capacity expansion
Forget saving humanity, the unfolding tragedy has made it clear that India - even with the world's largest vaccine maker at its disposal - cannot save itself
Tamil Nadu, Haryana, Punjab, Bihar and North Eastern States are the states where vaccination wastage is 'quite high', the report said
A writ petition on Wednesday has been filed in the Bombay High Court seeking Z plus security for Serum Institute of India CEO Adar Poonawalla and his family
Here are the best of Business Standard's opinion pieces for Wednesday